Literature DB >> 27228364

AXIN2 Polymorphisms and Their Association with Colorectal Cancer in Mexican Patients.

Mónica Alejandra Rosales-Reynoso1, Abril Renee Arredondo-Valdez1, Laura Ivonne Wence-Chávez1, Patricio Barros-Núñez2, Martha P Gallegos-Arreola1, Silvia Esperanza Flores-Martínez1, Jose Sánchez-Corona1.   

Abstract

AIM: The aim of this study was to investigate the association of the rs2240308 and rs1133683 polymorphisms in the AXIN2 gene with colorectal cancer (CRC) in Mexican patients.
MATERIALS AND METHODS: Genomic DNAs from 201 CRC patients and 100 healthy blood donors were analyzed for AXIN2 gene polymorphisms by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Statistical associations were calculated using the odds ratio (OR) test.
RESULTS: The genotype distribution of the rs1133683 polymorphism C > T showed a statistical difference between the two study groups (p = 0.0019). Moreover, OR analyses demonstrated that individuals with either the C/T or T/T genotype have a decreased risk for CRC compared with individuals with the C/C genotype (OR = 0.47, 95% confidence interval [CI] = 0.25-0.86, p = 0.0134 and OR = 0.24, 95% CI = 0.10-0.57, p = 0.005, respectively). This association was also evident in a stratified analysis based on tumor-node-metastasis (TNM) stage. For the rs2240308 polymorphism C > T, the OR analysis showed a significantly increased risk for carriers of the T/T genotype (OR = 2.64, 95% CI = 1.12-6.24, p = 0.0236) and this association was also evident in the stratified analysis by TNM stage.
CONCLUSION: Our results indicate the possibility that variations in the AXIN2 gene may play a significant role in promoting or preventing CRC development.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27228364     DOI: 10.1089/gtmb.2016.0026

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  8 in total

1.  Genotypes and Haplotypes in the AXIN2 and TCF7L2 Genes are Associated With Susceptibility and With Clinicopathological Characteristics in Breast Cancer Patients.

Authors:  M A Rosales-Reynoso; V Rosas-Enríquez; A M Saucedo-Sariñana; M Pérez-Coria; M P Gallegos-Arreola; E Salas-González; P Barros-Núñez; C I Juárez-Vázquez; S E Flores-Martínez; J Sánchez-Corona
Journal:  Br J Biomed Sci       Date:  2022-01-25       Impact factor: 2.432

2.  New insights into the association between AXIN2 148 C/T, 1365 C/T, and rs4791171 A/G variants and cancer risk.

Authors:  Bin Xu; Wei Yuan; Li Shi; Li Zuo; Xing-Yu Wu; Wei Zhang; Qiaxian Wen
Journal:  Cancer Cell Int       Date:  2019-05-06       Impact factor: 5.722

3.  Variations in AXIN2 predict risk and prognosis of colorectal cancer.

Authors:  L Otero; E Lacunza; V Vasquez; V Arbelaez; F Cardier; F González
Journal:  BDJ Open       Date:  2019-10-16

4.  New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies.

Authors:  Xi Li; Yiming Li; Guodong Liu; Wei Wu
Journal:  BMC Cancer       Date:  2021-04-01       Impact factor: 4.430

Review 5.  Wnt/β-catenin signaling in cancers and targeted therapies.

Authors:  Fanyuan Yu; Changhao Yu; Feifei Li; Yanqin Zuo; Yitian Wang; Lin Yao; Chenzhou Wu; Chenglin Wang; Ling Ye
Journal:  Signal Transduct Target Ther       Date:  2021-08-30

Review 6.  Mutations and mechanisms of WNT pathway tumour suppressors in cancer.

Authors:  Jeroen M Bugter; Nicola Fenderico; Madelon M Maurice
Journal:  Nat Rev Cancer       Date:  2020-10-23       Impact factor: 60.716

Review 7.  Molecular regulation and pharmacological targeting of the β-catenin destruction complex.

Authors:  Eline C van Kappel; Madelon M Maurice
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 8.  Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.

Authors:  Jernej Gašperšič; Alja Videtič Paska
Journal:  Biochem Med (Zagreb)       Date:  2020-08-05       Impact factor: 2.313

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.